 |
197 Diseases |  |
398 Trials |
|
398 Trials |  |
21826 News |  |
| «12...255256257258259260261262263264265266267» |
- ||||||| Yervoy (ipilimumab) / BMS
Trial completion, Metastases: Study of Immunotherapy to Treat Advanced Prostate Cancer (clinicaltrials.gov) - Jul 8, 2014
P3, N=796, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed
- Yervoy (ipilimumab) / BMS
Trial primary completion date, Metastases: First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma (clinicaltrials.gov) - Jul 4, 2014
P2, N=36, Recruiting, Sponsor: Hoosier Oncology Group
Active, not recruiting --> Completed Trial primary completion date: Jun 2014 --> Jun 2016
- ||| indoximod (NLG8189) / Lumos Pharma
Trial initiation date, Checkpoint inhibition: Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma (clinicaltrials.gov) - Jul 4, 2014
P1/2, N=56, Recruiting, Sponsor: NewLink Genetics Corporation
Trial primary completion date: Jun 2014 --> Jun 2016 Initiation date: Apr 2014 --> Jul 2014
- |||| indoximod (NLG8189) / Lumos Pharma
Enrollment open, Trial initiation date, Checkpoint inhibition: Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma (clinicaltrials.gov) - Jul 4, 2014
P1/2, N=56, Recruiting, Sponsor: NewLink Genetics Corporation
Initiation date: Apr 2014 --> Jul 2014 Not yet recruiting --> Recruiting | Initiation date: Apr 2014 --> Jul 2014
- || lirilumab (BMS-986015) / Innate, BMS, Ono Pharma, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Combination therapy, Metastases: A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jul 3, 2014
P1, N=162, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting | Initiation date: Apr 2014 --> Jul 2014 Trial primary completion date: Sep 2015 --> Jan 2017
- Yervoy (ipilimumab) / BMS
Trial primary completion date, IO biomarker: Neoadjuvant Ipilimumab in Prostate Cancer (clinicaltrials.gov) - Jul 2, 2014
P2a, N=20, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Sep 2015 --> Jan 2017 Trial primary completion date: Sep 2014 --> Sep 2015
- || Provenge (sipuleucel-T) / Bausch Health
Trial primary completion date: NCI-2014-00318: Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer (clinicaltrials.gov) - Jun 27, 2014
P2, N=54, Recruiting, Sponsor: Lawrence Fong
Trial primary completion date: Sep 2014 --> Sep 2015 Trial primary completion date: Aug 2014 --> Dec 2015
- ||| Provenge (sipuleucel-T) / Bausch Health
Trial initiation date: NCI-2014-00318: Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer (clinicaltrials.gov) - Jun 27, 2014
P2, N=54, Recruiting, Sponsor: Lawrence Fong
Trial primary completion date: Aug 2014 --> Dec 2015 Initiation date: Feb 2013 --> Jan 2014
- ||| Tecentriq (atezolizumab) / Roche
New P1 trial, Combination therapy, Metastases: A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jun 27, 2014
P1, N=200, Not yet recruiting, Sponsor: Hoffmann-La Roche
- | Biomarker, Enrollment open, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer (clinicaltrials.gov) - Jun 27, 2014
P2/3, N=10000, Recruiting, Sponsor: Southwest Oncology Group
Initiation date: Feb 2013 --> Jan 2014 Not yet recruiting --> Recruiting
- |||| Provenge (sipuleucel-T) / Bausch Health
Enrollment open, Trial initiation date, Trial primary completion date: NCI-2014-00318: Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer (clinicaltrials.gov) - Jun 27, 2014
P2, N=54, Recruiting, Sponsor: Lawrence Fong
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting | Initiation date: Feb 2013 --> Jan 2014 | Trial primary completion date: Aug 2014 --> Dec 2015
- |||| Yervoy (ipilimumab) / BMS
Trial completion, Metastases: Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer (clinicaltrials.gov) - Jun 27, 2014
P1/2, N=66, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Recruiting | Initiation date: Feb 2013 --> Jan 2014 | Trial primary completion date: Aug 2014 --> Dec 2015 Active, not recruiting --> Completed
- Yervoy (ipilimumab) / BMS
Enrollment change, Pan tumor, Metastases: DeCOG: THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease (clinicaltrials.gov) - Jun 24, 2014
P2, N=171, Completed, Sponsor: Prof. Dr. med. Dirk Schadendorf
Active, not recruiting --> Completed N=41 --> 171
- Yervoy (ipilimumab) / BMS
Trial completion, Enrollment change, Pan tumor, Metastases: DeCOG: THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease (clinicaltrials.gov) - Jun 24, 2014
P2, N=171, Completed, Sponsor: Prof. Dr. med. Dirk Schadendorf
N=41 --> 171 Active, not recruiting --> Completed | N=41 --> 171
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Metastases: KEYNOTE 029: Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) (clinicaltrials.gov) - Jun 24, 2014
P1/2, N=195, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed | N=41 --> 171 N=345 --> 195
- Leukine (sargramostim) / Partner Therap, Yervoy (ipilimumab) / BMS
Trial initiation date: Ipilimumab and GMCSF Immunotherapy for Prostate Cancer (clinicaltrials.gov) - Jun 23, 2014
P2, N=54, Not yet recruiting, Sponsor: Lawrence Fong
N=345 --> 195 Initiation date: Dec 2012 --> Feb 2014
- CD19CAR-28-zeta T cells / Baylor College of Medicine
Enrollment change: CRETI-NH: CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL (clinicaltrials.gov) - Jun 22, 2014
P1, N=54, Recruiting, Sponsor: Baylor College of Medicine
Initiation date: Dec 2012 --> Feb 2014 N=18 --> 54
- |||| Yervoy (ipilimumab) / BMS
Trial primary completion date, Metastases: Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab (clinicaltrials.gov) - Jun 13, 2014
P3, N=700, Active, not recruiting, Sponsor: Bristol-Myers Squibb
N=18 --> 54 Trial primary completion date: Sep 2015 --> Dec 2015
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date: Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) (clinicaltrials.gov) - Jun 13, 2014
P1, N=175, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Sep 2015 --> Dec 2015 Trial primary completion date: Jul 2016 --> Jun 2015
- Yervoy (ipilimumab) / BMS
Phase classification, Metastases: Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma (clinicaltrials.gov) - Jun 13, 2014
P2, N=40, Recruiting, Sponsor: University of Washington
Trial primary completion date: Jul 2016 --> Jun 2015 Phase classification: P1/2 --> P2
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Trial primary completion date: Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) (clinicaltrials.gov) - Jun 13, 2014
P1, N=175, Recruiting, Sponsor: Bristol-Myers Squibb
Phase classification: P1/2 --> P2 Active, not recruiting --> Recruiting | Trial primary completion date: Jul 2016 --> Jun 2015
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date, Monotherapy, PD(L)-1 Biomarker: Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) (clinicaltrials.gov) - Jun 11, 2014
P1, N=350, Recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Recruiting | Trial primary completion date: Jul 2016 --> Jun 2015 Trial primary completion date: Nov 2016 --> Nov 2015
- | Avastin (bevacizumab) / Roche, Yervoy (ipilimumab) / BMS
New P2 trial, Surgery, Metastases: Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Jun 7, 2014
P2, N=176, Recruiting, Sponsor: Academic and Community Cancer Research United
- Yervoy (ipilimumab) / Ono Pharma, BMS
Trial primary completion date, Combination therapy, Metastases: Mel-Ipi-Rx: Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma (clinicaltrials.gov) - Jun 5, 2014
P1, N=30, Recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Trial primary completion date: Nov 2016 --> Nov 2015 Trial primary completion date: Dec 2012 --> Mar 2016
- Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment open, Combination therapy, Metastases: Mel-Ipi-Rx: Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma (clinicaltrials.gov) - Jun 5, 2014
P1, N=30, Recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Trial primary completion date: Dec 2012 --> Mar 2016 Active, not recruiting --> Recruiting
- Avastin (bevacizumab) / Roche, Yervoy (ipilimumab) / BMS
Enrollment open, Surgery, Metastases: Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Jun 4, 2014
P2, N=176, Recruiting, Sponsor: Academic and Community Cancer Research United
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- Yervoy (ipilimumab) / Ono Pharma, BMS
Trial suspension, Metastases: Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases (clinicaltrials.gov) - Jun 3, 2014
P0, N=12, Suspended, Sponsor: Case Comprehensive Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Suspended
- || Biomarker, New P2/3 trial, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer (clinicaltrials.gov) - Jun 1, 2014
P2/3, N=10000, Not yet recruiting, Sponsor: Southwest Oncology Group
- || Keytruda (pembrolizumab) / Merck (MSD)
Trial primary completion date, Metastases: A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) (clinicaltrials.gov) - May 28, 2014
P1/2, N=320, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Suspended Trial primary completion date: Dec 2019 --> Nov 2016
- || Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Metastases: A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) (clinicaltrials.gov) - May 28, 2014
P1/2, N=320, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Dec 2019 --> Nov 2016 Trial completion date: Dec 2019 --> Jun 2019
- ||| Yervoy (ipilimumab) / BMS
Monotherapy: Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases (clinicaltrials.gov) - May 26, 2014
P2, N=99, Completed, Sponsor: Bristol-Myers Squibb
Trial completion date: Dec 2019 --> Jun 2019 N=72 --> 99
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date: Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064) (clinicaltrials.gov) - May 26, 2014
P2, N=140, Recruiting, Sponsor: Bristol-Myers Squibb
N=72 --> 99 Trial primary completion date: Aug 2016 --> Apr 2015
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date: Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064) (clinicaltrials.gov) - May 26, 2014
P2, N=140, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Aug 2016 --> Apr 2015 Trial completion date: Aug 2017 --> Apr 2016
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, Monotherapy: CheckMate 032: A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - May 26, 2014
P1/2, N=218, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Aug 2017 --> Apr 2016 N=160 --> 218
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date, Monotherapy: CheckMate 032: A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - May 26, 2014
P1/2, N=160, Recruiting, Sponsor: Bristol-Myers Squibb
N=160 --> 218 Trial primary completion date: Apr 2015 --> Oct 2015
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Monotherapy: CheckMate 032: A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - May 26, 2014
P1/2, N=160, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Apr 2015 --> Oct 2015 Trial completion date: Apr 2015 --> Oct 2015
- Yervoy (ipilimumab) / BMS
Trial termination, IO biomarker: MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma (clinicaltrials.gov) - May 21, 2014
P1/2, N=18, Terminated, Sponsor: National Cancer Institute (NCI)
Trial completion date: Apr 2015 --> Oct 2015 Completed --> Terminated
- Yervoy (ipilimumab) / BMS
Enrollment change, IO biomarker: MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma (clinicaltrials.gov) - May 21, 2014
P1/2, N=36, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated N=18 --> 36
- Leukine (sargramostim) / Partner Therap, Yervoy (ipilimumab) / BMS
Trial primary completion date, Combination therapy, Metastases: Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - May 18, 2014
P1, N=42, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=18 --> 36 Trial primary completion date: Nov 2013 --> Jan 2011
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Monotherapy, PD(L)-1 Biomarker: Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) (clinicaltrials.gov) - May 13, 2014
P1, N=350, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Nov 2013 --> Jan 2011 Trial completion date: Nov 2017 --> Dec 2016
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, Monotherapy, PD(L)-1 Biomarker: Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) (clinicaltrials.gov) - May 13, 2014
P1, N=350, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Nov 2017 --> Dec 2016 N=250 --> 350
- ||| Selectikine (EMD 521873) / EMD Serono
Trial initiation date, Combination therapy, Metastases: EMR 062235-005: MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma (clinicaltrials.gov) - May 12, 2014
P2, N=86, Recruiting, Sponsor: EMD Serono
N=250 --> 350 Initiation date: Nov 2013 --> Jan 2014
- Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment open: A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma (clinicaltrials.gov) - May 11, 2014
P1, N=24, Recruiting, Sponsor: Duke University
Initiation date: Nov 2013 --> Jan 2014 Not yet recruiting --> Recruiting
- || Imlygic (talimogene laherparepvec) / Amgen
Trial primary completion date: Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma (clinicaltrials.gov) - May 8, 2014
P1/2, N=149, Recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2015 --> Apr 2016
- || Imlygic (talimogene laherparepvec) / Amgen
Trial completion date: Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma (clinicaltrials.gov) - May 8, 2014
P1/2, N=149, Recruiting, Sponsor: Amgen
Trial primary completion date: Dec 2015 --> Apr 2016 Trial completion date: Mar 2017 --> Jul 2017
- Yervoy (ipilimumab) / BMS
Trial primary completion date, Metastases: Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients (clinicaltrials.gov) - May 6, 2014
P2, N=18, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Mar 2017 --> Jul 2017 Trial primary completion date: Jun 2014 --> May 2014
- Yervoy (ipilimumab) / BMS
Trial primary completion date, Metastases: Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma (clinicaltrials.gov) - May 6, 2014
P2, N=23, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jun 2014 --> May 2014 Trial primary completion date: Jul 2016 --> Jul 2014
- Yervoy (ipilimumab) / BMS
Trial primary completion date, Metastases: Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma (clinicaltrials.gov) - May 6, 2014
P2, N=26, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jul 2016 --> Jul 2014 Trial primary completion date: Jan 2015 --> May 2014
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial initiation date: CheckMate 143: A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients (clinicaltrials.gov) - May 6, 2014
P2b, N=264, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jan 2015 --> May 2014 Initiation date: Feb 2014 --> Jan 2014
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial initiation date, Monotherapy, PD(L)-1 Biomarker, IO biomarker: Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) (clinicaltrials.gov) - May 6, 2014
P3, N=915, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Feb 2014 --> Jan 2014 Initiation date: Jun 2013 --> May 2013